Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	530.73M +45.8%
Revenue (ttm)	294.28M +64.1%
Net Income	367.02M +1,999.1%
EPS	19.48 +1,867.7%
Shares Out	18.47M
PE Ratio	1.47
Forward PE	7.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	471,740
Open	26.94
Previous Close	27.36
Day's Range	26.90 - 28.75
52-Week Range	15.50 - 52.24
Beta	1.27
Analysts	Strong Buy
Price Target	45.67 (+58.96%)
Earnings Date	May 5, 2026

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Financial Performance

In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.

Analyst Summary

According to 3 analysts, the average rating for RIGL stock is "Strong Buy." The 12-month stock price target is $45.67, which is an increase of 58.96% from the latest price.

Price Target

$45.67

(58.96% upside)

Analyst Consensus: Strong Buy